Deep Track Capital, LP 13F: Quarter-over-Quarter Portfolio Changes
Deep Track Capital, LP reported a disclosed portfolio value of approximately $4.8 billion in its latest SEC Form 13F-HR filing for Q1 2026, up 10.5% quarter on quarter. Over the quarter, the fund initiated 15 new positions, bought more shares in 24 holdings, trimmed 14 holdings, and exited 6 positions.
Deep Track Capital, LP's top buy was a new stake in Alumis INC (ALMS) , equal to 3.1% of the disclosed portfolio. Its top sell was Dynavax Technologies CORP (DVAX) . The fund exited the position completely after it had accounted for 5.5% of the previous portfolio.
New PositionsQ1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| ALUMIS INC | ALMS | 3.1% | History → |
| NUVALENT INC | NUVL | 2.9% | Holders → |
| GENMAB A/S | GMAB | 2.0% | Holders → |
| DEFINIUM THERAPEUTICS INC | DFTX | 1.2% | Holders → |
| CORVUS PHARMACEUTICALS I | CRVS | 0.8% | Holders → |
| ACLARIS THERAPEUTICS INC | ACRS | 0.7% | Holders → |
| VERADERMICS INC | MANE | 0.7% | Holders → |
| SOLID BIOSCIENCES INC | SLDB | 0.5% | Holders → |
| APOGEE THERAPEUTICS INC | APGE | 0.5% | Holders → |
| KURA ONCOLOGY INC | KURA | 0.4% | Holders → |
| CENTURY THERAPEUTICS INC | IPSC | 0.4% | Holders → |
| BEAM THERAPEUTICS INC | BEAM | 0.4% | Holders → |
| PERSONALIS INC | PSNL | 0.4% | Holders → |
| PROMIS NEUROSCIENCES INC | PMN | 0.2% | Holders → |
| LARIMAR THERAPEUTICS INC | LRMR | 0.1% | Holders → |
Top BuysQ1 2026
Showing the top 10 buys among 24 existing positions where the fund bought more shares in Q1 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| JANUX THERAPEUTICS INC | JANX | +0.3% | +1225.3% | Holders → |
| ATAIBECKLEY INC | ATAI | +0.4% | +156.6% | Holders → |
| INVENTIVA SA | IVA | +0.1% | +149.5% | Holders → |
| OCULAR THERAPEUTIX INC | OCUL | +1.2% | +143.9% | History → |
| COGENT BIOSCIENCES INC | COGT | +0.4% | +120.7% | Holders → |
| ALKERMES PLC | ALKS | +1.3% | +79.5% | Holders → |
| GRAIL, INC. | GRAL | +-0.2% | +68.4% | Holders → |
| COMPASS PATHWAYS PLC | CMPS | +0.2% | +65.8% | Holders → |
| CENTESSA PHARMACEUTICALS PLC | CNTA | +1.4% | +57.9% | Holders → |
| BICARA THERAPEUTICS INC | BCAX | +0.7% | +55.4% | Holders → |
Top SellsQ1 2026
Showing the top 10 sells among 14 existing positions where the fund sold shares in Q1 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| CYTOKINETICS INC | CYTK | -3.0% | 58.8% | Holders → |
| BIOMARIN PHARMACEUTICALS | BMRN | -1.8% | 50.0% | Holders → |
| VIRIDIAN THERAPEUTICS INC | VRDN | -1.2% | 44.8% | Holders → |
| APELLIS PHARMACEUTICALS INC | APLS | -0.7% | 41.5% | History → |
| CELLDEX THERAPEUTICS INC | CLDX | -0.3% | 32.4% | Holders → |
| CYBIN INC | HELP | -0.2% | 29.2% | Holders → |
| DYNE THERAPEUTICS INC | DYN | -0.4% | 24.5% | Holders → |
| MAZE THERAPEUTICS INC | MAZE | -1.9% | 18.1% | Holders → |
| MBX BIOSCIENCES INC | MBX | -0.6% | 15.1% | Holders → |
| NURIX THERAPEUTICS INC | NRIX | -1.0% | 9.8% | Holders → |
Full ExitsQ1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| DYNAVAX TECHNOLOGIES CORP | DVAX | 5.5% |
| MIND MEDICINE MINDMED INC | BRD1EUR | 0.5% |
| XENON PHARMACEUTICALS INC | XENE | 0.4% |
| MONOPAR THERAPEUTICS INC | MNPR | 0.1% |
| RAPT THERAPEUTICS INC | RAPT | 0.1% |
| ADLAI NORTYE LTD | ANL | 0.0% |
Net Portfolio Value ChangeQ1 2026
- $4.4BPrior quarter
- $4.8BCurrent quarter
- +$0.5BNet delta
- +10.5%% change
Methodology & FAQ
How Deep Track Capital, LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Deep Track Capital, LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description — including how confidential treatment filings are handled — is documented in the Methodology.
What stocks did Deep Track Capital, LP buy in Q1 2026?
In Q1 2026, Deep Track Capital, LP initiated 15 new positions (ALUMIS INC (ALMS), NUVALENT INC (NUVL), GENMAB A/S (GMAB), DEFINIUM THERAPEUTICS INC (DFTX), CORVUS PHARMACEUTICALS I (CRVS), ACLARIS THERAPEUTICS INC (ACRS), VERADERMICS INC (MANE), SOLID BIOSCIENCES INC (SLDB), APOGEE THERAPEUTICS INC (APGE), KURA ONCOLOGY INC (KURA), CENTURY THERAPEUTICS INC (IPSC), BEAM THERAPEUTICS INC (BEAM), PERSONALIS INC (PSNL), PROMIS NEUROSCIENCES INC (PMN), LARIMAR THERAPEUTICS INC (LRMR)); bought more shares of JANUX THERAPEUTICS INC (JANX), ATAIBECKLEY INC (ATAI), INVENTIVA SA (IVA), OCULAR THERAPEUTIX INC (OCUL), COGENT BIOSCIENCES INC (COGT) — the largest 5 of 24 adds.
What stocks did Deep Track Capital, LP sell in Q1 2026?
In Q1 2026, Deep Track Capital, LP fully sold 6 positions (DYNAVAX TECHNOLOGIES CORP (DVAX), MIND MEDICINE MINDMED INC (BRD1EUR), XENON PHARMACEUTICALS INC (XENE), MONOPAR THERAPEUTICS INC (MNPR), RAPT THERAPEUTICS INC (RAPT), ADLAI NORTYE LTD (ANL)); reduced holdings in CYTOKINETICS INC (CYTK), BIOMARIN PHARMACEUTICALS (BMRN), VIRIDIAN THERAPEUTICS INC (VRDN), APELLIS PHARMACEUTICALS INC (APLS), CELLDEX THERAPEUTICS INC (CLDX) — the largest 5 of 14 reductions.
Which positions did Deep Track Capital, LP initiate in Q1 2026?
Deep Track Capital, LP established 15 new positions in Q1 2026: ALUMIS INC (ALMS, 3.1%), NUVALENT INC (NUVL, 2.9%), GENMAB A/S (GMAB, 2.0%), DEFINIUM THERAPEUTICS INC (DFTX, 1.2%), CORVUS PHARMACEUTICALS I (CRVS, 0.8%), ACLARIS THERAPEUTICS INC (ACRS, 0.7%), VERADERMICS INC (MANE, 0.7%), SOLID BIOSCIENCES INC (SLDB, 0.5%), APOGEE THERAPEUTICS INC (APGE, 0.5%), KURA ONCOLOGY INC (KURA, 0.4%), CENTURY THERAPEUTICS INC (IPSC, 0.4%), BEAM THERAPEUTICS INC (BEAM, 0.4%), PERSONALIS INC (PSNL, 0.4%), PROMIS NEUROSCIENCES INC (PMN, 0.2%), LARIMAR THERAPEUTICS INC (LRMR, 0.1%).
Which existing positions saw the largest allocation increases for Deep Track Capital, LP in Q1 2026?
Of 24 existing positions with share-count increases in Q1 2026, the largest were: JANUX THERAPEUTICS INC (JANX, +0.3% weight, +1225.3% shares), ATAIBECKLEY INC (ATAI, +0.4% weight, +156.6% shares), INVENTIVA SA (IVA, +0.1% weight, +149.5% shares), OCULAR THERAPEUTIX INC (OCUL, +1.2% weight, +143.9% shares), COGENT BIOSCIENCES INC (COGT, +0.4% weight, +120.7% shares), ALKERMES PLC (ALKS, +1.3% weight, +79.5% shares), GRAIL, INC. (GRAL, +-0.2% weight, +68.4% shares), COMPASS PATHWAYS PLC (CMPS, +0.2% weight, +65.8% shares), CENTESSA PHARMACEUTICALS PLC (CNTA, +1.4% weight, +57.9% shares), BICARA THERAPEUTICS INC (BCAX, +0.7% weight, +55.4% shares).
Which positions did Deep Track Capital, LP fully exit in Q1 2026?
Deep Track Capital, LP fully exited 6 positions in Q1 2026: DYNAVAX TECHNOLOGIES CORP (DVAX, last-reported weight 5.5%), MIND MEDICINE MINDMED INC (BRD1EUR, last-reported weight 0.5%), XENON PHARMACEUTICALS INC (XENE, last-reported weight 0.4%), MONOPAR THERAPEUTICS INC (MNPR, last-reported weight 0.1%), RAPT THERAPEUTICS INC (RAPT, last-reported weight 0.1%), ADLAI NORTYE LTD (ANL, last-reported weight 0.0%).
Which existing positions saw the largest allocation reductions for Deep Track Capital, LP in Q1 2026?
Of 14 existing positions with share-count reductions in Q1 2026, the largest were: CYTOKINETICS INC (CYTK, -3.0% weight, -58.8% shares), BIOMARIN PHARMACEUTICALS (BMRN, -1.8% weight, -50.0% shares), VIRIDIAN THERAPEUTICS INC (VRDN, -1.2% weight, -44.8% shares), APELLIS PHARMACEUTICALS INC (APLS, -0.7% weight, -41.5% shares), CELLDEX THERAPEUTICS INC (CLDX, -0.3% weight, -32.4% shares), CYBIN INC (HELP, -0.2% weight, -29.2% shares), DYNE THERAPEUTICS INC (DYN, -0.4% weight, -24.5% shares), MAZE THERAPEUTICS INC (MAZE, -1.9% weight, -18.1% shares), MBX BIOSCIENCES INC (MBX, -0.6% weight, -15.1% shares), NURIX THERAPEUTICS INC (NRIX, -1.0% weight, -9.8% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.